Dicerna Pharmaceuticals, Inc. (DRNA) News
Filter DRNA News Items
DRNA News Results
|Loading, please wait...|
DRNA News Highlights
- DRNA's 30 day story count now stands at 4.
- Over the past 20 days, the trend for DRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
Latest DRNA News From Around the Web
Below are the latest news stories about Dicerna Pharmaceuticals Inc that investors may wish to consider to help them evaluate DRNA as an investment opportunity.
LEXINGTON, Mass., September 22, 2021--Dicerna today announced new executive leadership appointments.
LEXINGTON, Mass. --(BUSINESS WIRE)--Sep. 2, 2021-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the Company or Dicerna), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., President and Chief Executive
Global RNA Therapeutics Market Growing Impressive Business Opportunities, Industry Trends, Global Demand, Future Scope with Top Players: Quark, Alnylam Pharmaceuticals, Inc Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma, Sanofi
An influential RNA Therapeutics market report covers an array of factors that have an influence on the market and Pharmaceutical industry which includes industry insight and critical success factors (CSFs), market segmentation and value chain analysis, industry dynamics, drivers, restraints,
The stock market’s behavior might appear baffling at times, but when you see shares of a biotech sinking, the reason is almost always one of two ready-made options: regulatory rejection or disappointing clinical trial results. For disappointed investors of Dicerna Pharmaceuticals (DRNA), the latter case sent the stock tumbling by 28% in a single session last week. Specifically, the downturn came about after the company released data from the phase 2 trial evaluating nedosiran as a treatment for
Shares of Dicerna Pharma (DRNA) declined 12.6% on Monday and closed at $23.83 after the company reported lower-than-expected Q2 results. The biopharmaceutical company engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease and viral liver infectious diseases. The company reported a net loss of $0.53 per share in the second quarter, which came much below analysts’ estimates of $0.41 per share. Its revenues of $41.3 million grew 2.2% year-over-year but lagged the consensus estimates of $44.4 million. Rise in Lilly, Novo, and BI revenues were largely offset by decreases in Roche and Alexion revenues.
DRNA earnings call for the period ending June 30, 2021.
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -203.92% and -68.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass., August 09, 2021--Dicerna today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI ) was among the biggest biopharma gainers of the week, with the stock reacting to a positive late-stage readout for its lung cancer treatment combo. The stock ended the week with a gain of about 128%. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ), however, was not as fortunate, as the stock lost about one-fifth of its market cap following mixed results from a pivotal trial of its RNAi therapeutic candidate nedosiran in primary hyperoxaluria 1. The market reacted negatively to earnings from vaccine...
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The trial hit the primary endpoint for a pivotal study, but shares plummeted after efficacy data in a sought-after patient subpopulation showed no benefit over placebo. PH is a family of ultra-rare genetic disorders that initially manifest with complications in the Full story available on Benzinga.com